Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for treatment of adults with moderate-to-severe plaque psoriasis who are candidates systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo apremilast and well tolerated in previous reports from phase 3 POETYK PSO-1 trial. Here, we examin...

This short article hypothesizes that the major reason for persistent disease despite biologic therapy is the inappropriately late timing of therapy with biologic agents. There is clear evidence to support this hypothesis. This short review will indicate that patients treated at an earlier phase of disease can achieve a clinical remission rate of 70% and a response rate of above 95%.

974, Glass RJ et al.10 Key Point Patients treated with TNF inhibitors remain on therapy long term, suggesting durable effects and tolerability. Anti-TNF Therapy in Biologic-Naïve and Experienced Patients Clinical trials of anti-TNF therapy typically excluded patients who had prior exposure to a TNF inhibitor. In clinical practice, clinicians often encounter patients with RA who have been treate...

OBJECTIVE Poor adherence to therapy increases the patient and societal burden and complexity of chronic diseases such as rheumatoid arthritis (RA). In the past 15 years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have revolutionized the treatment of RA. However, little data are available on the impact of adherence to biologics on health care resources. The objective of the study w...

It is now known that all biologic drugs, even those that are fully human, are immunogenic, that is, they have the ability to induce an immune response in the treated patient. Since the presence of antidrug antibodies may influence the levels and function of the drug in the body, this immune response can alter the efficacy of the biologic treatment and even its safety profile, depending on the m...